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patients and 201 weeks for SCR patients. Factors differentiating
the BuMelTT and SCR groups included median followup post-
ASCT, total percent relapse after transplant, death after transplant,
relapse in prior radiation ﬁeld, and stage at salvage therapy pre-
ASCT. To date, 37% of the BuMelTT and 56% of SCR patients
have relapsed (P  .05) with a median time to relapse of 30 and 36
weeks (P  NS), respectively. Median OS, EFS, and RFS have not
yet been reached for BuMelTT patients compared with 439 (P 
.03), 67 (P  NS), and 74 (P  NS) weeks for the SCR patients
respectively. TRM was 5% in both groups at 5 years. Secondary
myelodysplasia has been seen in one patient transplanted with
BuMelTT and one with SCR. In multivariate analysis the
BuMelTT regimen and chemosensitive disease were associated
with improved OS (HR  0.19 and 0.31, respectively). Relapse in
prior radiation ﬁeld predicted for poor EFS and OS (HR  3.43).
We investigated the predictive value of 4 PM on the entire group,
BuMelTT and SCR cohorts. Each of these models has identiﬁed 3
poor prognostic indicators on the basis of multivariate analysis.
Patients with 0 or 1 factor were considered good risk and 2 or 3
factors poor risk. Only the SWOG model was predictive for OS for
the entire group (P  .01) and for the BuMelTT (P0.05) and
SCR (P  .01) cohorts. The SWOG model was also able to
differentiate EFS between good and poor risk patients for the
entire group (P  .02) and SCR group (P  .05) but not for the
BuMelTT cohort. None of the models could differentiate between
good and poor risk patients with regard to RFS. When good and
poor risk was deﬁned as 0 factors versus 1 to 3 factors, the RPCI
model was predictive of OS (P  .02) and EFS (P  .02) but only
for the BuMelTT cohort. The PM evaluated had limited utility in
our patient cohort with only the SWOG model being predictive of
outcome. Large multi-institutional studies are needed to improve
PM for transplantation in advanced HD.
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PACLITAXEL FOLLOWED BY FILGRASTIM FOR PERIPHERAL BLOOD
STEM CELL (PBSC) MOBILIZATION IN PATIENTS WITH HEMATOLOGIC
MALIGNANCIES WHO EXPERIENCED PRIOR MOBILIZATION FAILURES
McKibbin, T.1,2, Burzynski, J.A.1,2, Twombly, R.G.1,2, Ochoa, J.L.1,2,
Tsai, T.W.1,2, Callander, N.S.1,2, Freytes, C.O.1,2 1. South Texas
Veterans Health Care System, San Antonio, TX; 2. University of Texas
Health Science Center, San Antonio, TX.
Cyclophosphamide followed by ﬁlgrastim (G-CSF) is frequently
utilized for PBSC mobilization in patients with hematologic ma-
lignancies, but is associated with adverse events such as hemor-
rhagic cystitis and a rate of febrile neutropenia as high as 30%. In
addition, white blood cell recovery varies among patients making it
difﬁcult to predict when to initiate apheresis. Our institution pre-
viously reported the efﬁcacy of paclitaxel followed by G-CSF for
PBSC mobilization in 30 patients with hematologic malignancies.
In 86% of those patients, paclitaxel mobilization was the initial
mobilization attempt. We report our experience with paclitaxel
250 mg/m2 IV once followed by G-CSF 10-16 mcg/kg/day in 27
consecutive patients treated at Audie L. Murphy Memorial Veter-
ans Hospital between 1/98 and 9/05. Twenty-one (78%) failed
mobilization with G-CSF 16 mcg/kg/day alone, 5 (18%) failed
mobilization with cyclophosphamide 3 g/m2 followed by G-CSF,
and 1 (4%) failed mobilization with rituximab, ifosfamide, carbo-
platin, and etoposide followed by G-CSF. Eight patients had mul-
tiple myeloma (MM), 17 had non-hodgkin’s lymphoma, and 2 had
acute myelogenous leukemia. Similar to our prior experience, 74%
of patients began apheresis on day 8 after paclitaxel administration,
based on a rising peripheral white blood cell count. The remaining
patients began apheresis on day 9 or 10 after paclitaxel adminis-
tration. Eighteen (67%) of 27 patients collected the target number
of CD34cells, deﬁned as 2  106 cells/kg. An additional 4
patients underwent PBSC transplant with fewer than 2  106
CD34 cells/kg (median 1.83, range 1.43&ndsh;1.98). One pa-
tient successfully collected adequate PBSC but elected to undergo
allogeneic PBSC transplant; thus 21 (78%) of 27 patients pro-
ceeded to high-dose chemotherapy followed by autologous PBSC
transplant. Median neutrophil (ANC 	 0.5  109/L) and platelet
(platelet20 109/L) recovery was 11 days (range 8–12) and 13 days
(range 9–24), respectively. Three patients (11%) developed febrile
neutropenia following paclitaxel resulting in one death prior to
high-dose chemotherapy in a patient with MM. Conclusions:
Paclitaxel followed by G-CSF is an effective mobilization strategy
for patients with hematologic malignancies who failed to mobilize
PBSC with other mobilization regimens. The low incidence of
febrile neutropenia and the predictable kinetics of white blood cell
recovery make this combination an attractive alternative for pa-
tients who fail to mobilize PBSC.
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HIGH-DOSE CHEMOTHERAPY (HDCT) WITH HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH POOR PROGNO-
SIS EWING FAMILY TUMORS (EFT)
Bolotin, E.1, Shakhnovits, M.1, Cooper, L.1, Qian, D.1, Hitt, D.,
Sweetman, R.1, Sato, J.K.1, Miser, J.1, Forman, S.1, Rosenthal, J.1 City
of Hope National Center and Beckman Research Institute, Duarte, CA.
Objective: To evaluate the feasibility and safety of treatment
with two cycles of HDCT followed by autologous HSCT in
patients (pts) with poor prognosis EFT. A retrospective analysis
included 20 EFT pts treated at City of Hope National Medical
Center with 2 cycles of HDCT and HSCT from 1997 to 2003.
HDCT for the ﬁrst cycle consisted of melphalan (MEL)/carbopla-
tin (CARB) in 9 pts and Mel/busulfan (BU) in 11 pts. HDT for the
second cycle consisted of MEL/CARB (n  5); MEL/BU (n  3);
and cyclophosphamide/etoposide/CARB (n  5). A descriptive
analysis of the safety, rate of recurrence, transplant-related mor-
bidity (TRM) and mortality, event-free survival (EFS), and overall
survival (OS) are reported. Results: Out of 20 eligible patients, 13
(65%) received 2 cycles of HDCT followed by autologous HSCT.
Seven (35%) patients did not proceed to a second cycle as planned:
2 (28.5%) patients refused, 2 (28.5%) patients died of rapidly
progressive disease, 1 (14%) patient died of idiopathic pulmonary
ﬁbrosis, 1 (14%) patient had previous radiation, and 1 (14%)
patient had renal failure. The median follow-up (n  20) was 2.4
years (range 0.1–7.8 years). Grade 4 adverse events were limited to
mucositis and pancytopenia. No TRM was recorded after the ﬁrst
cycle of HDT and HSCT. There was one death after second cycle
due to rapidly progressive disease. A sustained absolute neutrophil
count (ANC 	 1000/mm3) for both cycles was achieved at the
median of 11 days. A sustained platelet count (	50,000/mm3) was
achieved at a median of 17 to 20 days. There were no differences
in OS rates between various HDCT regimens used and between
patients with or without metastatic disease disease at the time of
diagnosis. The Kaplan-Meier estimates of OS and EFS at three
years were 45% (CI 0.22, 0.69) and 47% (CI 0.25,0.70), respec-
tively. For patients who have received two cycles of HDCT fol-
lowed by HSCT, the Kaplan-Meier estimates of OS and EFS at 3
years were 58% (CI 0.30, 0.86) and 58% (CI 0.30, 0.86), respec-
tively. Conclusions: Dose-intensiﬁcation with two cycles of
HDCT and HSCT is feasible and relatively safe, with low and
acceptable treatment related morbidity and mortality. Adding a
second course of therapy does not impair engraftment. Both OS
and EFS compare favorably with previously published reports.
HDCT with HSCT may improve outcome in patients with poor
prognosis EFT. Further studies are required to establish the opti-
mal regimen for HDCT.
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A LONG-TERM EXPERIENCE USING AUTOLOGOUS STEM CELL TRANS-
PLANTATION FOR THE MANAGMENT OF HODGKIN’S LYMPHOMA
Skikne, B.1, Divine1, C.1, Thudi, N.1, Deauna-Limayo, D.1,
Bodensteiner, D.1, Ganguly, S.1, Williams, C.2, Abhyankar, S.2,
McGuirk, J.2 1. The University of Kansas Medical Center, Kansas City,
KS; 2. Kansas City Cancer Center, Kansas City, MO.
Hodgkin’s disease (HD) patients generally have a good long-
term prognosis with approximately 70% cure rate. However, the
prognosis signiﬁcantly declines after disease relapse. High-dose
chemotherapy with autologous stem cell transplantation is an ef-
fective salvage option for patients in relapse with 5-year OS of
50%, and has become an accepted therapy. While transplantation
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has acceptable short-term survival, it is important to report longer
outcome durations and delayed complications. In this report, ret-
rospective analyses after transplantation from 2 centers from 1985
to 2003 were evaluated. Sixty-nine patients were evaluated, median
age 33 years (16–75), 43 men and 26 women, 55 had nodular
sclerosing HD, 7-lymphocyte predominant, 6-mixed cellular HD,
and 1-unknown subtype. Conditioning regimens consisted of TBI/
Cyclophosphamide in 11 patients, CBV in 38, BEAM/BEAC in 16,
and Busulfan/Cyclophosphamide in 4. Forty-nine patients received
peripheral stem cells (PSC), 17 received bone marrow (BM), and 3
received PSC plus BM. Seven patients (10%) had early mortality
(100 days) directly attributable to the transplant procedure. Four
were cardiac-related and two due to infection. Long-term non-
disease related mortality occurred in 16% secondary to MDS/
AML, cardiac, respiratory, and infectious-related causes. Thirty-
seven patients are alive, 30 patients have died, and 2 are lost to
follow-up. The OS at 5 years was 49% and 21% at 10-years,
respectively, while DFS at 5 years was 41% and 33% at 10 years,
respectively, indicating that patients were dying of other causes late
after transplantation. No difference in OS and DFS was noted
according to disease status at transplantation (CR vs active disease),
gender, or PSC vs BM. However, signiﬁcant differences were
noted in OS (P  .05) and DFS (P  .05) according to sensitivity
to salvage therapy administered prior to transplantation. Achieve-
ment of CR after transplantation had a signiﬁcant effect on OS. At
the median follow-up of 32 months, the OS is 83%, with a pre-
dicted OS at 10 years of 68%. Failure to achieve CR after trans-
plantation was associated with reduced OS, with 38% alive at 32
months, and all died by 10 years post-transplant. In conclusion,
autologous transplantation offers a good long-term survival option
for patients with relapsed/resistant HD. However, if CR is not
attained after transplantation, alternative therapies should be pur-
sued, because long-term outcomes for this patient group is dismal.
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AMIFOSTINE DOES NOT PROTECT AGAINST LIVER TOXICITY IN PA-
TIENTS RECEIVING DOSE-ESCALATED IV BUSULFAN (IVBU) AND STAN-
DARD DOSE CYCLOPHOSPHAMIDE IN AUTO BMT
Grosso, D.1, Brunner, J.1, Dessain, S.1, Ferber, A.1, Filicko, J.1,
Mookerjee, B.1, Shaw, L.2, Tedesco, N.1, Tran, H.3, Wagner, J.1,
Flomenberg, N.1 1. Thomas Jefferson University, Philadelphia, PA; 2.
University of Pennsylvania Medical Center, Philadelphia, PA; 3. M. D.
Anderson Cancer Center, Houston, TX.
Eight adult patients undergoing autologous transplant for hema-
tological malignancies were given a conditioning regimen of 4 daily
single doses of IVBU followed 24 hours later by 2 days of cyclo-
phosphamide (CP) at 60 mg/kg/day adjusted body weight. Ami-
fostine 740 mg/m2 was given just prior to each dose of IVBU and
CP in an attempt to ameliorate toxicities and allow for IVBU
dose-escalation. Dose-escalation of IVBU was based on AUC and
was done in phase I fashion. There were 4 planned cohorts, with a
targeted average daily AUC range for cohort 1 of 4400–5280
uMol-minute per day (midpoint 4800). This represents the AUC
range commonly achieved by single daily doses of 3.2mg/kg/day.
Each successive cohort of patients was to receive a dose of IVBU
that would result in an AUC that was 20% greater than the
previous group. Patients were given a test dose of 0.4 mg/kg of
IVBU over 15 minutes between 7 and 21 days prior to condition-
ing. Pharmacokinetics (PK) performed around the test dose were
used to base the ﬁrst 2 conditioning doses of IVBU. Additional
IVBU PK data was collected around conditioning doses 1and 3. If
the targeted AUC range was not achieved based on the IVBU PK
data for dose 1, IVBU doses were adjusted for days 3 and 4.
Acetaminophen and metronidazole were held during all IVBU
administration. Fungal prophylaxis was the same during IVBU test
and conditioning doses. Patients received phenytoin for seizure
prophylaxis. Five patients were enrolled in cohort 1. Three patients
achieved the desired AUC for this cohort. The other 2 exceeded
the target with AUCs that were within cohort 2 range. Despite
this, there was no VOD and only grade 0 to 1 mucositis or diarrhea
in this group. Three patients were enrolled in cohort 2 and met the
targeted average daily AUC range of 5281–6340 uMol-minute per
day (midpoint 5800) for that range. Two of 3 patients in cohort 2
developed late onset VOD (days 25, 22) and the protocol was
closed. One of these patients died from complications of VOD. In
cohort 2, there was 1 patient with grade 2 mucositis. Grade 0 to 1
mucositis and diarrhea was observed in the other patients. Amifos-
tine appears to ameliorate mucositis and diarrhea in patients re-
ceiving standard doses of IVBU and CP in autologous BMT but
does not protect against VOD in patients receiving dose-escalated
IVBU at least when combined with CP.
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DURATION OF ULCERATIVE MUCOSITIS AND OUTCOMES OF AUTOLO-
GOUS (AU) HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOLLOWING HIGH-DOSE MELPHALAN (MP) CONDITIONING FOR MUL-
TIPLE MYELOMA (MM)
Oster, G.1, Vera-Llonch, M.1, Ford, C.2, Lu, J.3, Khazanov, I.2,
Sonis, S.2 1. Policy Analysis, Inc (PAI), Brookline, MA; 2. Brigham and
Women’s Hospital, Boston, MA; 3. Amgen Inc, Thousand Oaks, CA.
Background: OM is a common toxicity of conditioning regi-
mens for HSCT that has been associated with adverse clinical and
economic outcomes. Methods: A retrospective study of approxi-
mately 400 consecutive HSCT recipients was undertaken at a
single academic center. Data were collected via chart review on
days with ulcerative mucositis and selected outcomes including
days with fever, days of parenteral narcotic therapy, incidence of
Grade III or IV (Common Toxicity Criteria) infection, total inpa-
tient days (LOS), and total inpatient charges. Data are reported
here for the 115 MM patients who underwent AU HSCT after
high-dose MP conditioning. Results: Mean age of study subjects
was 54 years. Seventeen percent of patients received total body
irradiation. Bone marrow was the source of most grafts. The
relationship between duration of ulcerative mucositis and the out-
comes of interest is reported below. Conclusions: Duration of
ulcerative OM is associated with worse clinical and economic
outcomes in MM patients undergoing AU HSCT following high-
dose MP conditioning (Table1).
Table 1. Outcomes of AU HSCT Following High-Dose Conditioning
for MM, by Days with Ulcerative Mucositis
Days with Ulcerative Mucositis (Quartile)
I II III IV
Outcomes n  32 n  33 n  25 n  25 P-value*
Fever days (mean,SD) 1.0 (1.9) 1.9 (3.2) 2.5 (2.5) 3.1 (3.7) .0058
Narcotic therapy days
(mean,SD) 0.7 (1.7) 3.9 (3.5) 4.4 (3.5) 8.8 (5.2) <.0001
Infection (%) 10.0 (31.3) 10.0 (30.3) 12.0 (48.0) 9.0 (36.0) .4115
LOS (mean,SD) 18.3 (3.1) 19.8 (3.5) 19.9 (3.4) 23.1 (3.5) <.0001
Inpatient charges
(mean,SD)
( 10,000) 11.7 (3.2) 12.3 (3.8) 11.8 (2.1) 15.5 (6.0) .0016
*Test for linear trend; Cochran-Armitage for dichotomous and
GLM for continuous measures.
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AUGMENTED HIGH DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND
CARMUSTINE FOLLOWED BY TRANSPLANTATION WITH PERIPHERAL
BLOOD STEM CELLS (PBSC) IN THE TREATMENT OF RELAPSED OR
REFRACTORY HODGKIN’S DISEASE
Schwartz, J.E.1, Robertson, M.J.1, Cornetta, K.G.1, Cripe, L.D.1,
Nelson, R.P.1, Yiannoutsos, C.T.1, Baute, J.A.1, Wood, L.L.1,
Abonour, R.1 Indiana University, Indianapolis, IN.
Introduction: The majority of patients with advanced stage
Hodgkin’s disease are cured with conventional dose combination
chemotherapy. However, patients with disease that fails to enter a
complete remission or that recurs after ﬁrst-line chemotherapy
have a poor prognosis. High dose chemotherapy with autologous
stem cell transplantation is a highly promising treatment. We
report the results of an augmented regimen containing cyclophos-
phamide, etoposide and carmustine followed by PBSC transplan-
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